Treatment of gram-positive nosocomial pneumonia: Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 3 I, 2000, Pages 753-762

  Fagon, J Y ^a   Patrick, H ^b   Haas, D W ^b   Torres, A ^b   Gibert, C ^b   Cheadle, W G ^b   Falcone, R E ^b   Anholm, J D ^b   Paganin, F ^b   Fabian, T C ^b   Lilienthal, F ^b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; DALFOPRISTIN PLUS QUINUPRISTIN; IMIPENEM; TOBRAMYCIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; MYALGIA; PNEUMONIA; PRIORITY JOURNAL;

EID: 0034021097     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.3.9904115     Document Type: Article

References (38)

1. Craven, D. E., and K. A. Steger. 1995. Epidemiology of nosocomial pneumonia: new perspectives on an old disease. Chest 108:1S-16S.
2. Chastre, J., and J. Y. Fagon. 1994. Pneumonia in the ventilator-dependent patient. In M. Tobin, editor. Principles and Practice of Mechanical Ventilation, 1st ed. McGraw & Hill, New York. 847-890.
3. American Thoracic Society. 1996. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: a consensus statement. Am. J. Respir. Crit. Care Med. 153:1711-1725.
4. Rello, J., V. Ausina, M. Ricart, J. Castella, and G. Prats. 1993. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 104:1230-1235.
5. Levinson, M. E., and D. Kaye. 1985. Pneumonia caused by gram-negative bacilli: an overview. Rev. Infect. Dis. 7:S656-S665.
6. Jarvis, W. R., and W. J. Martone. 1992. Predominant pathogens in hospital infections. J. Antimicrob. Chemother. 29(A): 19-24.
7. Vincent, J. L., D. J. Bihari, P. M. Suter, H. A. Braining, J. White, M. H. Nicolas-Chanoin, M. Wolff, R. C. Spencer, and M. Hemmer. 1995. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care Study. J.A.M.A. 274:639-644.
8. Spencer, R. C. 1996. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur. J. Clin. Microbiol. Infect. Dis. 15:281-285.
9. Fagon, J. Y., J. Chastre, Y. Domart, J. L. Trouillet, J. Pierre, C. Darne, and C. Gibert. 1989. Nosocomial pneumonia in patients receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of protected specimen brush and quantitative culture techniques. Am. Rev. Respir. Dis. 139:877-884.
10. Torres, A., J. Puig de la Bellacasa, A. Xaubert, J. Gonzales, J. Rodriguez-Roisin, M. T. Jimenez de Anta, and A. Augusti-Vidal. 1989. Diagnostic value of quantitative cultures of bronchoalveolar lavage and telescoping plugged catheters in mechanically ventilated patients with bacterial pneumonia. Am. Rev. Respir. Dis. 140:306-310.
11. Rello, J., and A. Torres. 1996. Microbial causes of ventilator-associated pneumonia. Semin. Respir. Infect. 11:24-31.
12. Archibald, L., L. Phillips, D. Monnet, J. E. McGowan, Jr., F. Tenover, and R. Gaynes. 1997. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit. Clin. Infect. Dis. 24:211-215.
13. Rello, J., A. Torres, M. Ricart, J. Valles, J. Gonzales, A. Artigas, and R. Rodriguez-Roisin. 1994. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am. J. Respir. Crit. Care Med. 150:1545-1549.
14. Iwahara, T., S. Ichiyama, T. Nada, K. Shimokata, and N. Nakashima. 1994. Clinical and epidemiologic investigations of nosocomial pulmonary infections caused by methicillin-resistant Staphylococcus aureus. Chest 105:826-831.
15. Layton, M. C., W. J. Hierholzer, and J. E. Patterson. 1995. The evolving epidemiology of methicillin-resistant Staphylococcus aureus at a university hospital. Infect. Control Hosp. Epidemiol. 16:12-17.
16. Boyce, J. M., R. L. White, and E. Y. Spruill. 1983. Impact of methicillin-resistant Staphylococcus aureus on the incidence of nosocomial staphylococcal infections. J. Infect. Dis. 148:763.
17. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
18. Centers for Disease Control. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin. United States. CDC Update. MMWR C.D.C. Surveill. Summ. 46:813-815.
19. Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, et al. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340:493-501.
20. Centers for Disease Control and Prevention. 1995. Recommendations for preventing the spread of Vancomycin resistance. Infect. Control Hosp. Epidemiol. 16:105-113.
21. Bouanchaud, D. H. 1997. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin. J. Antimicrob. Chemother. 39(Suppl A):15-21.
22. Celis, R., A. Tiorres, J. M. Gatell, M. Almera, R. Rodriguez-Roisin, and A. Agusti-Vidal. 1988. Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest 93:318-324.
23. Leu, H. S., D. L. Kaiser, M. Mori, R. F. Woolson, and R. P. Wenzel. 1989. Hospital acquired pneumonia: attributable mortality and morbidity. Am. J. Epidemiol. 129:1258-1267.
24. Fagon, J. Y., J. Chastre, A. Vuagnat, J. L. Trouillet, A. Novara, and C. Gibert. 1996. Nosocomial pneumonia and mortality among patients in intensive care units. J.A.M.A. 275:866-869.
25. Alvarez-Lerma, F. 1996. ICU-acquired pneumonia study group. Modifications of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 22:387-394.
26. Luna, C. M., P. Vujacich, M. S. Niederman, C. Vay, C. Gherardi, J. Matera, and E. C. Jolly. 1997. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111:676-685.
27. Wunderink, R. G., C. G. Mayhall, and C. Gibert. 1992. Methodology for clinical investigation of ventilator-associated pneumonia. Epidemiology and therapeutic intervention. Chest 102(Suppl. 1):580S-588S.
28. Cone, L. A., D. R. Woodard, D. S. Stolzman, and R. G. Byrd. 1985. Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia. Antimicrob. Agents Chemother. 28:33-36.
29. Fink, M. P., D. R. Snydman, M. S. Niederman, K. V. Leeper, Jr., R. H. Johnson, S. O. Heard, et al. 1994. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind, trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob. Agents Chemother. 38:547-557.
30. Lode, H., R. Wiley, G. Hoffken, J. Wagner, and K. Borner. 1987. Prospective randomized controlled study of ciprofloxacin versus imipenem/ cilastatin in severe clinical infections. Antimicrob. Agents Chemother. 31:1491-1496.
31. Knaus, W. A., E. A. Draper, D. P. Wagner, and J. E. Zimmerman. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-829.
32. Kollef, M. H., P. Silver, D. M. Murphy, and E. Trovillion. 1995. The effect of late-onset pneumonia in determining patient mortality. Chest 108:1655-1662.
33. Craven, D. E., L. M. Kunches, V. Kilinsky, B. J. Lichteberg, B. J. Make, and W. R. McCabe. 1986. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am. Rev. Respir. Dis. 133:792-796.
34. Montravers, P., J. Y. Fagon, J. Chastre, M. Lesco, M. C. Dombret, J. L. Trouillet, and C. Gibert. 1993. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am. Rev. Respir. Dis. 147:38-44.
35. Fink, M. P., D. R. Snydman, M. S. Niederman, K. V. Leeper, Jr., R. H. Johnson, S. O. Heard, R. G. Wunderink, J. W. Caldwell, J. J. Schentag, G. A. Siami, R. L. Zameck, D. C. Haverstock, H. H. Reinhart, R. M. Echols and the Severe Pneumonia Study Group. 1994. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob. Agents Chemother. 38:547-557.
36. Brun-Buisson, C., J. P. Sollet, S. Brière, and C. Petit for the VAP Study Group. 1998. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multi-center, randomized controlled trial. Clin. Infect. Dis. 26:346-354.
37. Niederman, M. S., J. B. Bass, Jr., G. D. Campbell, A. M. Fein, R. F. Grossman, I. A. Mandell, J. J. Marrie, G. A. Sarosi, A. Torres, and V. L. Yu. 1993. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am. Rev. Respir. Dis. 148:1418-1426.
38. Bompart, F., M. Dorr, T. Bekele, J. Rey, C. Vessereau, et al. 23 June 1997. Overview of the safety and tolerability of quinupristin/dalfopristin in the global development program. Presented at the 20th International Congress of Chemotherapy, Sydney.